• DiD (DiDC 18 (5)) Membrane Staining Guide

  2026-08-21

  DiD (DiDC 18 (5)) provides red plasma-membrane labeling for live-cell tracking, neuronal tracing, migration assays, and immunofluorescence workflows. This practical guide connects membrane-resolved imaging with inflammatory macrophage research while emphasizing solvent control, fixation choices, and troubleshooting for reproducible data.

• GSK343 EZH2 Inhibitor: Cancer Research Workflows

  2026-08-21

  GSK343 is a cell-permeable EZH2 inhibitor for connecting PRC2-dependent histone H3K27 trimethylation inhibition with cancer-cell phenotypes. This workflow-focused guide covers dose selection, chromatin readouts, immune-related assay extensions, and troubleshooting for reproducible in vitro studies.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-08-20

  A 2025 study shows that naturally occurring angiotensin peptides can alter SARS-CoV-2 spike binding to host receptors, with peptide length and modification at tyrosine 4 shaping the effect. The findings connect renin-angiotensin system biology with viral receptor interactions, while remaining a biochemical hypothesis that requires validation in cellular and in vivo models.

• Targeted SPP1 Inhibition Reprograms Tumor Myeloid Cells

  2026-08-20

  The reference study combines phenotypic screening in reporter macrophages with TAM-avid nanodelivery to identify a practical strategy for lowering SPP1 in tumor-associated myeloid cells. Its lead formulation, CANDI460, reduced SPP1 expression and produced tumor remissions in multiple murine models, while also illustrating the translational challenges of selectively reprogramming immunosuppressive macrophages.

• D-Luciferin Potassium Salt for Glioma BLI

  2026-08-19

  D-Luciferin potassium salt provides a water-soluble, workflow-friendly substrate for tracking luciferase-labeled glioma cells and measuring treatment response in vivo. This guide connects substrate handling with the 2025 paclitaxel micelle study, practical BLI design, reporter assays, and troubleshooting.

• Tofacitinib Repairs RA Macrophage Dysfunction

  2026-08-19

  A 2026 study identifies GM-CSF-reprogrammed rheumatoid arthritis macrophages as an inflammatory and metabolically dysregulated population marked by oxidative stress, mitochondrial fragmentation, and reduced regulatory features. Tofacitinib reversed this phenotype through suppression of GM-CSFRα and STAT5 signaling, providing a mechanistic framework for cytokine signaling blockade in RA research.

• Berberine hydrochloride: Reliable Cell Assays

  2026-08-18

  A scenario-driven guide to using Berberine hydrochloride (SKU N1699) in cell viability, proliferation, and cytotoxicity workflows. It connects formulation control, assay interpretation, and recent AMPK and gut–bone evidence without overstating translational conclusions.

• Nanoparticle Uptake by Human Corneal Epithelial Cells

  2026-08-18

  Azadi and David investigated how PLGA nanoparticle size and surface chemistry influence uptake by human corneal epithelial cells using a mucosa-relevant in vitro model. Their results identify energy-dependent endocytosis, particularly macropinocytosis and caveolae-mediated uptake, as the dominant mechanisms and highlight 100 nm PLGA and PEG-PLGA nanoparticles as promising design benchmarks.

• Shh and Fgf10 Control Species-Specific Penile Development

  2026-08-17

  Wang and Zheng identify differential Shh and Fgf10/Fgfr2 expression as a major determinant of why guinea pigs form an open urethral groove whereas mice form the urethra without an equivalent distal groove. Their combination of comparative gene-expression mapping and ex vivo genital-tubercle perturbation provides a useful framework for studying species-specific genital development and congenital urogenital anomalies.

• CSBTA Pharmacokinetics in MASH Mice

  2026-08-17

  A 2025 study integrated pharmacokinetics, tissue distribution, transporter assays, microsomal metabolism, and PXR-related regulation to explain why Corydalis saxicola Bunting total alkaloids behave differently in MASH mice. Its findings indicate that disease state and repeated dosing can increase systemic and hepatic exposure, providing a mechanistic framework for dose optimization in MASLD/MASH research.

• STING agonist-1 and the IRF4+ B-Cell Axis

  2026-08-16

  STING agonist-1 offers translational researchers a controlled way to interrogate STING biology beyond conventional interferon readouts. This thought-leadership analysis connects STING pathway activation in innate immunity with CD40–TRAF2–IRF4 signaling, B-cell activation, and tertiary lymphoid structures in esophageal squamous cell carcinoma, while outlining a disciplined path from molecular validation to cancer immunotherapy research.

• ISRIB (trans-isomer) in Memory and ER Stress

  2026-08-15

  ISRIB (trans-isomer) links molecular ISR control with practical studies of inflammation-associated forgetting, ER stress, and apoptosis. This workflow-focused guide shows how to use the compound as a PERK inhibitor and eIF2B-pathway modulator while separating memory rescue from nonspecific sickness or toxicity.

• Nelfinavir Mesylate: HIV-1 Protease Inhibition

  2026-08-14

  Nelfinavir Mesylate is an orally bioavailable HIV-1 protease inhibitor with nanomolar antiviral activity in cell-based models. Its established virology mechanism and emerging DDI2-related ferroptosis findings support carefully separated applications in HIV infection research and cell-death studies.

• Site-Specific PEGylation Blocks IL-11 in Lung Fibrosis

  2026-08-14

  The reference study engineered receptor-biased interleukin-11 by introducing a site-specific cysteine and PEGylating the GP130-binding interface, while largely preserving IL-11Rα recognition. In bleomycin-challenged mice, the optimized PEGylated analogs reduced extracellular-matrix deposition and preserved alveolar structure, supporting a targeted strategy for modulating profibrotic cytokine signaling.

• MK-0812: A Translational Lens on MASH Inflammation

  2026-08-13

  A thought-leadership guide to using MK-0812 as a selective CCR2 perturbation tool in MASH research, connecting monocyte trafficking biology with the intestinal TM6SF2–gut–liver axis and practical preclinical assay design.

15714 records 1/1048 page Next 12345 下5页 Last page